Ricevi le ultime notizie sulle azioni Alumis con aggiornamenti su tendenze di mercato, dati finanziari e analisi di Benzinga. Rimani informato sulle performance di ALMS

Ultime notizie per

ALUMIS INC

Alumis

Alumis Inc is a clinical-stage biopharmaceutical company focused on identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. The Company leverages its proprietary precision data analytics platform, biological insights, and a team of experts with deep experience in precision medicine drug discovery, development, and immunology, to create medicines that significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Company pipeline includes: ESK-001, TYK2, A-OO5, IRF5.

wall street chart shutter2

News

Short Ideas

Pre-Market Outlook

Markets

Trading Ideas

ALMS

CMRX

DERM

Analisi dei segnali di allarme nel settore sanitario: cosa rivela l&#39;indicatore tecnico chiave per gli investitori. È il momento di agire?

3 titoli del settore sanitario che potrebbero crollare nel secondo trimestre

Alumis Inc

Press Releases

Leading Independent Proxy Advisory Firm ISS Recommends ACELYRIN Stockholders Vote "FOR" the Proposed Transaction with Alumis

ACELYRIN Stockholders Approve Merger with Alumis to Create Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases

Alumis Stockholders Approve Merger with ACELYRIN

Earnings

Alumis Reports First Quarter 2025 Financial Results and Highlights Recent Achievements

Alumis Completes Merger with ACELYRIN

Health Care

Alumis Completes Enrollment of Pivotal Phase 3 ONWARD Clinical Program of Lead Candidate ESK-001, a Highly Selective, Next-Generation Oral TYK2 Inhibitor for the Treatment of Moderate-to-Severe Plaque Psoriasis

Alumis to Present at the Jefferies Global Healthcare Investor Conference

Management

Alumis Announces the Promotion of Sanam Pangali to Chief Legal Officer and Corporate Secretary

Alumis Completes Patient Enrollment in the Global LUMUS Phase 2b Trial of ESK-001, a Next-Generation Oral TYK2 Inhibitor for the Treatment of Systemic Lupus Erythematosus

Alumis Reports Second Quarter 2025 Financial Results and Provides Corporate Update

SLRN

Aurora Cannabis

ALT5 Sigma

Aquestive Therapeutics, Inc. - Common Stock

Aquestive Therapeutics

Arvinas

Atea Pharmaceuticals, Inc. - common stock

Atea Pharmaceuticals

Canopy Growth Corporation - Common Shares

Canopy Growth

Contineum Therapeutics, Inc. - Common stock

Contineum Therapeutics

Evolus

Esperion Therapeutics, Inc. - Common Stock

Esperion Therapeutics

Eton Pharmaceuticals, Inc. - Common Stock

Eton Pharmaceuticals

Fulcrum Therapeutics, Inc. - Common Stock

Fulcrum Therapeutics

High Tide

Maze Therapeutics

MBX Biosciences

Nektar Therapeutics

Neumora Therapeutics, Inc. - Common Stock

Neumora Therapeutics

Omeros

Rapport Therapeutics, Inc. - Common Stock

Rapport Therapeutics

Septerna

SIGA Technologies

SNDL

Terns Pharmaceuticals, Inc. - Common Stock

Terns Pharma

Tvardi Therapeutics

Zevra Therapeutics

Zhengye Biotechnology Holding Limited - Ordinary Shares

Zhengye Biotechnology

Morgan Stanley

HC Wainwright & Co.

Wells Fargo

Guggenheim

Comments

Alumis Notizie sulle azioni

Notizie

Ultime notizie per

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO